Maxygen says Bayer unit to buy hemophilia assets
Biotechnology firm Maxygen said a unit of Germany's Bayer AG agreed to buy its hemophilia program for $120 million, including a potential milestone payment of $30 million.
The deal includes a license to use Maxygen's MolecularBreeding technology, used to target genes. (Reuters)
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.